-
Sanofi-aventis and Sunnybrook Health Sciences Centre to Develop Treatment for Diabetic Foot Ulcers
Tuesday, February 15, 2011 - 9:09am | 67Sanofi-aventis (NYSE: SNY) and Sunnybrook Health Sciences Centre (Toronto, Canada) announced that they have entered into a research agreement and licensing option for vasculotide, an investigational compound to treat chronic wounds. This includes neuropathic diabetic foot ulcers caused by a lack...
-
Piper Jaffray Reiterates Overweight on Salix Pharmaceuticals (SLXP)
Tuesday, February 15, 2011 - 8:56am | 88Piper Jaffray is out with its report today on Salix Pharmaceuticals (NASDAQ: SLXP), reiterating Overweight. In a note to clients, Piper Jaffray writes, "With strong sales growth, high Xifaxan gross margins (near 90% for the 550 mg dose), and moderate growth in R&D spend, we continue to see...
-
Mylan Launches First Generic Version of Vfend Tablets
Tuesday, February 15, 2011 - 8:36am | 75Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. (NYSE: PFE) Mylan was the first company to have filed a substantially complete...
-
Watson Pharmaceuticals Reports Q4 EPS of $0.93 vs. $0.93
Tuesday, February 15, 2011 - 8:29am | 116Watson Pharmaceuticals, Inc. (NYSE: WPI) today reported net revenue increased 21 percent to $952.7 million for the fourth quarter ended December 31, 2010, compared to $785.7 million in the fourth quarter 2009. On a non-GAAP basis, net income for the fourth quarter 2010 was $116.5 million or $0.93...
-
Valentine's KISS 02-14-2011
Monday, February 14, 2011 - 3:58pm | 814Cusick's Corner KISS: Keep It Simple – it's low volume on this grind to the upside, the market is overbought and commercial traders are pulling off their hedges (specifically in the NAZ and DOW futures), all going to put your discipline and your plan to test. Now those of you who have been winging...
-
Pre-Market Movers:(TPI),(EXK),(AXL),(OCZ)
Monday, February 14, 2011 - 10:18am | 34Pre-Market Movers:(TPI),(EXK),(AXL),(OCZ)
-
Jefferies Maintains $36 PT On AUXL
Monday, February 14, 2011 - 9:59am | 63Jefferies is maintaining its $36 PT on shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL). “Xiaflex continues to be the main stock driver for AUXL,” Jefferies writes. “We believe Xiaflex adoption is gated by reimbursement concerns rather than clinical concerns, and we anticipate steady Xiaflex...
-
TPI Reports Q2 EPS of $0.14
Monday, February 14, 2011 - 9:47am | 106Tianyin Pharmaceutical Co., Inc. (NYSE: TPI) announced the financial results for the second quarter of Fiscal Year 2011. Revenue increased 69.6% year over year to $25.3 million from $14.9 million in 2Q FY2010 Operating income increased 69.0% year over year to $5.3 million from $3.2 million in 2Q...
-
Benzinga's Top Upgrades (TRN, ANF, CAM, GSK)
Monday, February 14, 2011 - 9:22am | 144Trinity Industries Inc (NYSE: TRN) was upgraded by BB&T Capital from "hold" to "buy." TRN's shares closed at $30.46 on Friday. TRN's trailing-twelve-month revenue is $2.05 billion. Wells Fargo upgraded Abercrombie & Fitch Co (NYSE: ANF) from "market perform" to "outperform." ANF's shares...
-
Jefferies Raises PT On Merck & Company To $34.50
Monday, February 14, 2011 - 8:51am | 27Jefferies & Company has raised the price target on Merck & Company (NYSE: MRK) from $29.90 to $34.50 and maintains its Hold rating.
-
Exane BNP Paribas Ups GSK To Outperform
Monday, February 14, 2011 - 7:04am | 42Analysts at Exane BNP Paribas upgrade GlaxoSmithKline plc (NYSE: GSK) from “neutral” to “outperform.” GSK shares fell 1.00% to close at $37.75 on Friday. More Analyst Ratings here
-
Merger Arbitrage Mondays – February 14, 2011
Monday, February 14, 2011 - 6:24am | 4875Merger activity increased last week with seven new deals announced and five deals closing. You can find all the deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: Total Number of Deals Closed in 2011 19 Total Number of Pending...
-
Mad Money Lightning Round: Cramer Advises Investors To Buy Apple (NVO, FNSR, ARG, AAPL, OH)
Monday, February 14, 2011 - 1:47am | 152On CNBC's Mad Money, Jim Cramer said during the Lightning Round that Novo Nordisk (NYSE: NVO) is “one of the few drug companies making money.” He added, “I'd stay long that stock." For Finisar (NASDAQ: FNSR), he said, "There is a semiconductor bull market. I don't think it's done yet. I would stay...
-
International News Trumps Domestic 02-11-2011
Friday, February 11, 2011 - 6:45pm | 746Cusick's Corner It was quite an end to an eventful week. Next week could be a big week in the markets with Retail Sales due out pre-market on Monday -- watch the Retailers, XRT, want to see if this weather is cooling down store activity. Housing data also gets a small push Monday with the NAHB due...
-
Two ETFs for the Recovery in Big Pharma
Friday, February 11, 2011 - 3:59pm | 736It has been a long time coming, but the time is finally right to buy Big Pharma. The last few years have been rough for the sector; looming patent expirations and jitters over the potential effects of ObamaCare have caused investors to dump large-cap pharmaceutical stocks like discarded medical...